Navigation Links
Michael Showalter Joins Prime Therapeutics As Chief Marketing Officer
Date:7/21/2011

ST. PAUL, Minn., July 21, 2011 /PRNewswire/ -- Prime Therapeutics (Prime), announced today that Michael Showalter has joined the company as chief marketing officer (CMO). As CMO, Showalter has overall responsibility for Prime's marketing and product development efforts, focused on helping the company continue to grow as a leading pharmacy benefit manager. Showalter's proven expertise in consumer-oriented strategies will also help prepare Prime for success as the market evolves.

"Michael brings an extensive track record of business strategy, health care marketing and product development expertise to the Prime team," said Eric Elliott, president and CEO, Prime. "I am confident that his diverse skills will allow us to leverage the value of pharmacy – the most frequently accessed component of the health care chain - to help shape our clients' success in the consumer-centric post-reform market. Michael's experience will help us continue to see significant growth, as we have in recent years, through industry-leading product development and helping us communicate Prime's differentiators as an integrated PBM focused on value and transparency."

Previously, Showalter served as the senior vice president of Enterprise Strategic Planning at CIGNA. Prior to that, he was CMO and the general manager of Consumer Driven Product Lines at CIGNA HealthCare, and vice president of Product and Public Affairs at Definity Health. He received his bachelor's degree in Speech/Communication from the University of Minnesota.

Prime Therapeutics is a pharmacy benefit management company dedicated to providing innovative, clinically-based, cost-effective pharmacy solutions for clients and members. Providing pharmacy benefit services nationwide to approximately 17 million covered lives, its client base includes Blue Cross and Blue Shield Plans, employer and union groups, and third-party administrators. Headquartered in St. Paul, Minnesota, Prime Therapeutics is c
'/>"/>

SOURCE Prime Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. ViaCyte Names Michael Scott Vice President, Device Research & Development
2. U.S. Congressman Michael Capuano to Receive "Lou Gehrig Award" from ALS TDI During Gala Event this November
3. Brin Wojcicki Foundation Announces $50-Million Challenge Grant to Michael J. Fox Foundation to Spur Progress Toward Parkinsons Cure
4. Anaphore Appoints Michael F. Haller, Ph.D., Senior Vice President of Strategic Partnerships and H Casey Logan Senior Vice President of Business Development
5. Lyle Arnold, PhD and Michael Dunn Join Biocept Management Team
6. NxStage® Names Michael Miller, Jr. President, International
7. Mersana Therapeutics Appoints Michael A. Metzger as EVP & COO
8. Michael Douglas, Honored Film Star and Throat Cancer Survivor, Encourages Public to Attend Free Local Screenings During Oral, Head & Neck Cancer Awareness Week
9. Xenon Chief Scientific Officer, Dr. Michael Hayden Receives Prestigious Award for Leadership in Medicine
10. Valeant Pharmaceuticals Extends Contract with J. Michael Pearson as CEO and Appoints Him as Chairman of the Board
11. Hill-Rom Elects Michael Macek as Treasurer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... Texas , May 28, 2015   Lexicon ... that Lexicon management will present at the Jefferies 2015 ... a.m. Eastern Time in New York ... clinical development programs and milestones. A webcast ... at www.lexpharma.com . An archived version of the ...
(Date:5/28/2015)... DEKALB, Ill. , May 28, 2015 ... Intent to explore an affiliation with Northwestern Memorial ... and NMHC will further define the affiliation, which ... "KishHealth is recognized for their commitment to ... Dean M. Harrison , President and Chief Executive ...
(Date:5/28/2015)... MONICA, Calif. , May 28, 2015 ... doctors to check a state prescription database before prescribing ... addiction and thousands of overdose deaths. SB ... Bell Gardens , will require prescribers to ... (CURES) before prescribing Schedule II and III drugs, like ...
Breaking Medicine Technology:Lexicon To Present At The Jefferies 2015 Healthcare Conference 2KishHealth System Explores Affiliation with Northwestern Memorial HealthCare 2KishHealth System Explores Affiliation with Northwestern Memorial HealthCare 3California Senate Approves Legislation Requiring Physicians To Check State Database Before Prescribing Powerful, Addictive Medications, Says Consumer Watchdog 2
... Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: ... specializing in the development, manufacturing, and marketing of ... that Shanghai Celgen Bio-Pharmaceutical Co., Ltd. ("Shanghai Celgen") ... interest, has received new drug registration approval for ...
... Cempra Pharmaceuticals, a developer of differentiated antibiotics, ... (IV) solithromycin demonstrates excellent tolerability and ... up to 800 mg.  Oral administration of solithromycin ... 1 studies.  The presentation will be at the ...
Cached Medicine Technology:Simcere Announces Recent Progress of Qiangke's Registration 2Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 2Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 3Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 4Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 5Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 6Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 7
(Date:5/28/2015)... Recently, KORT Richmond, 5006 Atwood Drive, added a ... of life. The program works with those new to prosthetic ... but are still having difficulty. , According to the ... with limb loss in the United States. The main causes ... peripheral arterial disease – trauma (45%) and cancer (less than ...
(Date:5/28/2015)... Bronx, NY (PRWEB) May 28, 2015 ... Urgent Care are proud to present Dr. Alicia Almendral ... will be a big part of the newly opened ... very finest in modern cosmetic treatments. , Dr. Almendral ... experienced in the latest anti-aging and cosmetic enhancement techniques. ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 On Sunday, ... Longest Day®, a team event to honor the strength, ... annually on summer solstice, the duration of this sunrise-to-sunset ... the disease and their caregivers. Participants raise funds and ... of the Alzheimer’s Association. , Teams are encouraged to ...
(Date:5/28/2015)... 28, 2015 Dr. Jenyons’ Medical ... exclusive deal to patients looking to undergo its advanced ... 30, patients will be able to get a single ... just $600. For a three-treatment package, which costs $1,800, ... no cost. , Dr. Juanita Jenyons, M.D., says Dr. ...
(Date:5/28/2015)... Medelis, Inc., a specialty oncology CRO , ... the role of president. , “ Bill Taaffe has ... said Larry Flanagan, Medelis’ CEO and co-founder. “He will be ... phase of growth.” , Taaffe joined ICON’s U.S. clinical ... to over 4,500 employees, achieving 12 consecutive years of growth ...
Breaking Medicine News(10 mins):Health News:KORT Richmond Physical Therapy Adds New Program to Help Amputees 2Health News:Bella Diosa Med Spa Welcomes Botox Specialist to Yonkers Community 2Health News:Dr. Jenyons’ Medical Weight Loss & Rejuvenation Center Now Offering Skin Treatment Specials 2Health News:Dr. Jenyons’ Medical Weight Loss & Rejuvenation Center Now Offering Skin Treatment Specials 3Health News:Bill Taaffe, Former President and CEO of ICON Clinical Research-US, Joins Medelis, a Specialty Oncology CRO, in the Role of President 2
... Not enough Scottish children are receiving MMR shots, say ... 92.1 per cent of two-year-olds were given the jab, which protects ... 95 per cent. , Yet, this is an ... cent. ,MMR vaccines were introduced in 1988, but ...
... medicine of Sanofi-Aventis will be made indigenously in Thailand. This ... ,As per the offer made by Sanofa-Aventis, the health ministry ... the drug. The statement released by the drug firm states ... poorer Thai patients. According to a health official the company ...
... rice bran could reduce the risk of intestinal cancer.// ... Department of Cancer Studies and Molecular Medicine, University of Leicester. ... in the laboratory has produced promising results. ... Cancer. ,The results of a controlled laboratory ...
... cancer patients unable to undergo surgery have another safe ... a new study. ,The Brown Medical ... ablation used to treat early-stage, inoperable cancer resulted in ... achieved through external beam radiation (EBT), a decades-old alternative ...
... Scientists have created the world's first human-sheep chimera - which ... ,The sheep have 15 per cent human cells ... brings the prospect of animal organs being transplanted into humans ... the University of Nevada, has spent seven years and ?5 ...
... Rift Valley Fever (RVF) among animals began on 18 ... the beginning// of February 2007 in Arusha region. A ... Country Office, WHO Regional Office for Africa, Centers for ... including active case finding and specimen collection. Two cases ...
Cached Medicine News:Health News:Scotland’s Parents Still a Little Wary of MMR Shot 2Health News:RF Ablation a Safe Alternative Option for Treating Lung Cancer 2Health News:Now Scientists Create a Sheep That's 15% Human 2Health News:Rift Valley Fever in the United Republic of Tanzania 2
Used to introduce balloon, diagnostic and guiding catheters, or other devices for intervention....
Used to introduce large balloon, closed and non-tapered end catheters or other devices for intervention....
Used for the introduction of catheters, balloons and other vascular devices....
Used to introduce large devices for vascular intervention....
Medicine Products: